In short. How a low-cost, easy-to-prepare material ended up attached to almost every other treatment, and what that attachment does not prove.
Key points
- A good result after two treatments belongs to the two treatments together.
- Attributing part of it to the addition is an assumption, and the assumption is easiest to make precisely where the addition has been studied least.
This material is attached to an unusual range of treatments, and the explanation is more commercial than clinical. Understanding why it spread makes it easier to see what an offer of it does and does not tell you.
Why it spreads so easily
It requires no product stock and no manufacturing, so it can be offered by any practice with a centrifuge. It is inexpensive to prepare relative to most add-ons. And it can be described as the patient’s own blood, which is a persuasive framing and an accurate one. Those three properties make it an easy addition to a menu, and none of them is a clinical finding. A treatment that is cheap, available and easy to describe will be offered widely whether or not it has been shown to help.
The add-on problem
When something is added to a procedure rather than used alone, the evidence that it contributes is a comparison between the procedure with the addition and the procedure without it. That comparison is rarely made, because the addition is not the treatment being studied and nobody is required to demonstrate it. What is usually offered instead is a description of a good result after a combination, which establishes that the session went well and nothing about which part produced the outcome.
A combination is not a contribution
A good result after two treatments belongs to the two treatments together. Attributing part of it to the addition is an assumption, and the assumption is easiest to make precisely where the addition has been studied least.
Why the framing works
The material is described as natural, as your own, and as something being restored rather than something being introduced. Each of those descriptions is accurate in a narrow sense and each invites a conclusion the accuracy does not carry. A person who might weigh a treatment carefully may accept an addition described as their own blood without weighing it at all, which is precisely the decision the framing is designed to make easy.
What to ask when it is offered as an addition
Whether the main treatment is being changed in any way by the addition, and if not, what the addition is for. Whether there is evidence that the combination performs better than the main treatment alone. Whether the price of the session has changed. And what would be different about the outcome if the addition were left out, which is the question a service that has thought about it can answer and one that has not cannot.
Three questions about an add-on
- Is there evidence that this combination performs better than the main treatment alone?
- What is the addition expected to change, and how would you know whether it had?
- If it were left out, what is the honest expectation for the outcome?
A widely offered addition is a widely available one, which is a fact about supply rather than about benefit. The two are easy to confuse and worth keeping apart.
Frequently asked questions
Why is this material added to so many treatments?
Because it is cheap to prepare relative to other add-ons, it needs no product stock, and it can be described as the patient's own. Those are genuine operational advantages, and they explain the spread of the practice without saying anything about whether the addition helps.
Does a good result after a combination prove the addition worked?
No. Where two treatments are given in one session, a good result belongs to the session. Crediting either part requires a comparison between the combination and the main treatment alone, and that comparison is rarely available for an add-on.
Is being the patient's own blood a reason to include it?
It is a reason it carries two fewer risks than a donor-derived material, and it is not a reason it works. The origin of a material answers a question about safety and says nothing about whether adding it improves anything.
Risks & Limitations
- There is no cosmetic approval, and no authority has assessed the claims made for the treatment.
- The platelet concentration depends on the kit, device and spin used, and is not standardised or comparable between clinics.
- Blood handled outside a controlled laboratory is a medium in which bacteria grow, so preparation carries a risk of infection that the source of the blood does not remove.
- The material is reabsorbed over a short period, so it does not restore volume the way a filler does.
- Adding it to another treatment is not evidence that the combination works better than the main treatment alone.
When to Seek Care
- Redness, warmth, swelling or pain that is increasing rather than settling after an injection.
- Discharge from an injection site, or a fever — seek prompt clinical assessment.
- An uneven or lumpy result, or any change in the treated area that concerns you.
- Contact the service that performed the treatment, or the hospital’s outpatient channels, rather than relying on a website.
References & Further Reading
- U.S. Food and Drug Administration (FDA) — guidance on autologous cellular products and point-of-care preparation
- European Medicines Agency (EMA) and national regulators — guidance on blood-derived and autologous treatments
- National Medical Products Administration (NMPA, China) — regulation of blood-derived preparations and devices
- World Health Organization (WHO) — guidance on the safe preparation and handling of blood components
- Cochrane Library — systematic reviews of platelet-rich plasma for hair loss and skin indications
This page is patient education, not medical advice, and it does not cite individual studies. It reviews evidence and regulation; it is not a booking page and does not recommend a treatment. Discuss your own case with a qualified clinician. To ask a question about this review, see Contact & Consultation.